DRD2 and Alzheimer disease: For instance, LY171555 (a dopamine D2 receptor agonist) significantly decreased the kindling parameters (such as seizure intensity, seizure duration and AD duration) in fully kindled animals when this agonist is microinjected into the nucleus accumbens at 15 min before kindling.10